KFA-115, also known as NVP-KFA115, is an immunomodulatory agent being developed by Novartis for the treatment of select advanced cancers.
A Phase I, Open-label, Multi-center Study of KFA115 as a Single ... Detailed descriptions of each drug are provided, including their mechanisms of action ...
Mutations in the TGF-β receptor type II or its downstream target, SMAD4, can disrupt the negative feedback mechanism, thereby leading to increased TGF-β levels.
People also ask
What is the mechanism of action of HIF2a inhibitors?
What is the mechanism of action for Anakinra?
What is the mechanism of action of Tezepelumab?
What is the mechanism of action of bryostatins?
The pipeline report covers assessment of Ovarian Cancer therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
Jan 30, 2023 ˇ This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of ...
Nov 30, 2023 ˇ The purpose of this study is to characterize the safety and tolerability of KFA115 ... mechanism of action of the drug, clinical studies ...
The mechanism of action of curcumin against tumors is facilitated by three different mechanisms: (i) downregulation of anti-apoptotic proteins which leads ...
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers ... Mechanism of Action of High-Dose IL-2 ...
This search will output a list of trials for which you may be eligible based on the criteria you enter. ... KFA115; KO-2806; KQB198; KRAS TCR-Transduced PBL ...
To study the anti-cancer activity of the PARP inhibitor Talazoparib (TalzennaŽ) in breast cancer tumors that test positive for a tumor (not inherited) BRCA 1 or ...